Large Cap Biopharmaceuticals-Valuation Models 2016
Biopharmaceutical Valuations Look Attractive Sector Poised for Rebound by Year End This is a continuing review of large cap biopharmaceutical valuation metrics to determine which companies can deliver growth from their broad pipelines. The biotech sector has underperformed the market because of...
BRexit Bottom for Biotech Creates Buying Opportunity…Update-2
Update-2 ...6/30 after the close Biotech stocks rallied again for the third day but momentum ebbed. Large caps were mainly in the green led by Alexion Pharmaceuticals (ALXN), Roche Holding (RHHBY) and Gilead Sciences (GILD). Mid-caps were mixed and well below recent highs. All of our core...
Sharp Biotech Reversal To Upside Today: IBB up 2.40%…Update-2
6/26...Until the emotion of BRexit subsides there is little to do with trading biotechnology stocks. We need to first see if US healthcare stocks can stabilize so look at XLV which was down 2.94% on Friday to $69.29. Support is at the March 17 low of $66.30. After the close 6/22...BRexit Curbs...
Biotech Blahs: Unable To Hold Gains After ASCO Run-Up…Update-1
Monday June 20... Update 4:30p EDT...BRexit relief rally Biotech stocks pretty much tracked the NASDAQ rally today slowly selling off as the day wore on. The more volatile XBI was still up 1.56% for the day beating the sluggish IBB up 0.91%. The healthcare sector overall held up about 1%....
BIO 2016 #2: Notes on Healthcare Affordability Crisis
Healthcare Affordability Creates a Trust Gap Super Session -Seeking Healthcare Sustainability and the Economic Role of Drugs Consumers are becoming more distrustful of the government because of healthcare affordability. Recently politicians have focused on rising drug costs exacerbated...